190 related articles for article (PubMed ID: 37495776)
21. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
22. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
25. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
[TBL] [Abstract][Full Text] [Related]
26. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.
Veselá P; Tonar Z; Sálek D; Vokurka S; Trněný M; Kodet R; Moulis M; Kašparová P; Vernerová Z; Velenská Z; Stříteský J; Michal M; Boudová L
Virchows Arch; 2014 Nov; 465(5):587-97. PubMed ID: 25048573
[TBL] [Abstract][Full Text] [Related]
27. Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?
Haydaroglu Sahin H
Medicine (Baltimore); 2019 Jul; 98(30):e16180. PubMed ID: 31348229
[TBL] [Abstract][Full Text] [Related]
28. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.
Todorovic M; Balint B; Andjelic B; Stanisavljevic D; Kurtovic NK; Radisavljevic Z; Mihaljevic B
Med Oncol; 2012 Sep; 29(3):2212-9. PubMed ID: 22170090
[TBL] [Abstract][Full Text] [Related]
29. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
Sonbol MB; Maurer MJ; Stenson MJ; Allmer C; LaPlant BR; Weiner GJ; Macon WR; Cerhan JR; Witzig TE; Gupta M
Am J Hematol; 2014 Dec; 89(12):E223-7. PubMed ID: 25164110
[TBL] [Abstract][Full Text] [Related]
30. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E; Dreyling M; Klapper W; Gisselbrecht C; van Hoof A; Kluin-Nelemans HC; Pfreundschuh M; Reiser M; Metzner B; Einsele H; Peter N; Jung W; Wörmann B; Ludwig WD; Dührsen U; Eimermacher H; Wandt H; Hasford J; Hiddemann W; Unterhalt M; ;
Blood; 2008 Jan; 111(2):558-65. PubMed ID: 17962512
[TBL] [Abstract][Full Text] [Related]
31. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
[No Abstract] [Full Text] [Related]
32. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
33. Elevated SOX11 mRNA level correlates with favorable prognosis in mantle cell lymphoma.
He J; Xi Y; Gao N; Xu E; Xie L; Chang J; Liu J
J BUON; 2019; 24(4):1679-1685. PubMed ID: 31646825
[TBL] [Abstract][Full Text] [Related]
34. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.
Rauert-Wunderlich H; Mottok A; Scott DW; Rimsza LM; Ott G; Klapper W; Unterhalt M; Kluin-Nelemans HC; Hermine O; Hartmann S; Thorns C; Rymkiewicz G; Holte H; Dreyling M; Hoster E; Rosenwald A
Br J Haematol; 2019 Feb; 184(4):616-624. PubMed ID: 30095158
[TBL] [Abstract][Full Text] [Related]
35. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Gressin R; Caulet-Maugendre S; Deconinck E; Tournilhac O; Gyan E; Moles MP; El Yamani A; Cornillon J; Rossi JF; Le Gouill S; Lepeu G; Damaj G; Celigny PS; Maisonneuve H; Corront B; Vilque JP; Casassus P; Lamy T; Colonna M; Colombat P;
Haematologica; 2010 Aug; 95(8):1350-7. PubMed ID: 20220059
[TBL] [Abstract][Full Text] [Related]
37. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of clinical risk factors in mantle cell lymphoma.
Hoster E
Semin Hematol; 2011 Jul; 48(3):185-8. PubMed ID: 21782060
[TBL] [Abstract][Full Text] [Related]
39. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
[TBL] [Abstract][Full Text] [Related]
40. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
